Vaxart

Vaxart Inc is an American biotechnology company that focuses on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. The company's development programs include pill vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine. In February 2020, Vaxart began a program to develop an oral tablet vaccine for COVID-19, and in April of the same year, the company reported positive immune responses in laboratory animals from its tests with a vaccine candidate for COVID-19. The company's stock is traded on the NASDAQ under the ticker symbol VXRT.